Analyst Price Target is C$15.50
▲ +1,465.66% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Reunion Neuroscience in the last 3 months. The average price target is C$15.50, with a high forecast of C$20.00 and a low forecast of C$11.00. The average price target represents a 1,465.66% upside from the last price of C$0.99.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Reunion Neuroscience.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.